BRAF and colorectal carcinoma: For CRC, RFLP methods have been used for the detection of targeted therapy-related KRAS and BRAF gene mutations, and the corresponding KRAS mutation assay kit is commercially available [20, 22]; however, no PCR-RFLP method has been developed for PIK3CAH1047R.